TABLE 1 Ongoing clinical trials evaluating combination therapy in MDS or AML
From the following article:
Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies
Steven D Gore
BACK TO ARTICLE| Disease | Regimen | Phase | Study site |
|---|---|---|---|
AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; FHCRC, Fred Hutchinson Cancer Research Center; MDS, myelodysplastic syndrome; SLL, small lymphocytic lymphoma. | |||
| MDS, CML, AML |  MS-275 orally days 3 and 10 Azacitidine subcutaneously days 1–10 Cycle repeats every 28 days | I (open and recruiting patients) | Sidney Kimmel Cancer Center, Baltimore, MD, USA |
| AML, refractory CLL, SLL | Decitabine intravenously days 1–10 Valproic acid orally three times a day, days 5–21 Cycle repeats every 28 days | I (open and recruiting patients) | Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, OH, USA |
| MDS (advanced) | Azacitidine Etanercept (FHCRC protocol #1926) | I/II (open and recruiting patients) | Fred Hutchinson Cancer Research Center, Seattle, WA, USA |
